Could a single shot replace two for weight loss?

NCT ID NCT04940078

Completed Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving two weight-loss drugs, cagrilintide and semaglutide, in one combined injection works as well as giving them separately. Forty adults with overweight or obesity received weekly injections for 22 weeks. The main goal was to see how the drugs' levels in the blood compare between the two methods.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cagrilintide and semaglutide (weight-loss drugs)
What this could lead to: If successful, this could lead to a simpler, single-injection option for people taking both drugs for weight loss.
What could go wrong: This is a small, early-phase study focused on drug levels, not weight loss or safety. Results may not apply to larger populations or predict long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY & OVERWEIGHT

Contacts and locations

Locations

Altasciences Company Inc.

Montreal, Quebec, H3P 3P1, Canada
Novo Nordisk Investigational Site

Søborg, 2860, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.